Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI302 vs aflibercept in neovascular age-related macular degeneration
CTR20221283Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Jun 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of efdamrofusp alfa in exudative macular degeneration, sponsored by Innovent Biologics. Started Jun 2022; status: completed.
02
Drugs
efdamrofusp alfa
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20221283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221283.